Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I do not know. We are part of the MGH/Brigham system and they have done some stuff, but not at our hospital, so far as I know. Why not? No idea.
I am not a hospitalist or an intensivist and I do not take care of COVID patients beyond the ED. I I follow COVID therapy as it applies to me and my job. Which means little impact so far. For very sick patients we start dexamethasone and sometimes Remdesivir.
The ED is not a focus of COVID therapeutic trials, so far as I know. Thatis too bad, because it would appear that might be the place where B could help the most. Give it to people before they get very very sick
2021 starts where no one predicted. No big splash, priced below 18 lousy cents a share, despite FDA approved trial starting soon. Difficult to say exactly how Leo squandered all of his momentum but he did. Was it the very very slow pace of research? To the point where focus went to vaccines and other treatments? That is part of it, but just part.
Recall, folks, that as all those patients are in the hospital clinging to life, or suffering, for the most part they receive supportive care as their main treatment. Because there is not some other very helpful treatment. Hard to believe but it is true.
IP and B can still change the world but it has to get in the game.
NEJM 12/31 review article on pathophysiology of Inflammatory bowel diseases. Will IP ever get into this game? Obv simple to find money if B for C works. If B for C fails, has that opportunity- specifically, IP running its oral B for UC trial- been lost? Can they scrape up the cash?
I work in a community hospital. It is nothing like MGH or Brigham or BI in terms of unit beds. It varies with staffing, is the case- one nurse, 2 patients, so usu 6 - 12 unit beds. Heavy pressure usu on those beds, recently, to take patients, and heavy pressure to staff the ICU if full.
Corona viral load as a way to select patients for the trial? Interesting. Viral load followed carefully for HIV obv but I have read much less about its importance for COVID. Time to learn.
NYT 12/29 Mandavilli as a start
41 yo Louisiana politician- could B have helped him? Just one example, one, as thousands die daily. Start the trial already, please. IP. Again, in my own community ED, on the board yest, 90 yo SOB, 95 yo cough and weak, 89 yo dizzy and weak, 31 yo cough SOB, etc etc. all with COVID.
Imagine - much worse- Los Angeles, where they are desperate.
It is ugly out there in your local hospitals folks and we need to see if B helps-
you missed a date- 12/31/2020- no trial started. Company promised q4 start many months ago. Then reiterated this message over and over. Early in the summer they were talking about a trial.
This is the key date to recall as one powers the share price of almost nothing, despite the excitement of a potential corona virus treatment. The vaccines roll out and other treatments are established(not many, really, though) and B is not in a trial for C.
That is the critical missed date for IP- we are just upon it-
I think there are more opportunities in the ED setting than one might guess since so many sent home- no reason to stay unless quite ill. You could find people who almost needed admission but not quite. Maybe that will be their next study- if there is ever a next study
who says it's easy? I certainly did not. The issue is what is the best trial for B success. I t may be a one and done company f B fails the trial.
Huh? What you were responding to is the problem as I see it- yes, they plan a hospital based trial, and no, that might not be the optimal population of patients for B success. BUT: hard to do an output trial with a drug with no corona virus experience.
Not hyperventilating a billion concerns-at least I did not think I was. Instead just listing the very quick first few issues in selecting patients for the trial. Easy peasy obvious- and yet possibly critical to success or failure of the trial.
where? and treated with what? moderate in the US treated with Rem but not steroids? Moderate in Italy treated with nothing? Or in India? On oxygen only? On a vent ? off a vent only ? Includes those with proning? Or excludes? what O2 requirements? Excludes a certain flow?
Lots of potential variables we know nothing about, lots of potential ways to include/ exclude patients depending on where in hospital and how treated
O2nasal cannula only? BIPAP ok? High flow OK? How high? Vent yes vent no to enroll. Remdesivir, Dexamethasone, one or the other, neither?
Co morbidities OK? COPD OK? Renal function exclusions? Creatine of what puts you in or out? Diabetes in or out?
No- we do not know nearly enough about trial selection
100,000 hospitalized across the USA and where is B? About to start the wrong trial, possibly, although we are given no details at all yet about any trial. B + Dex + Remdesivir for some? Or will they search for patients in other countries treated differently?
Would B be better for a subset coming to an ED not sick enough to be admitted, but meeting certain criteria to enter the trial- let's say CRP > 80 and Abnl CXR and sats 95 at rest planned for discharge ? Those patents require some thought and eval. Hospitalize our not? Comorbidities? Other issues? Mostly all these patients go home, except for the frail elderly, or those with COPD/asthma/AODM/CHF etc.
Or what about a group that comes in early- scared, but not sick, a common scenario. Capture that group too- they have sats 98-100 mild sx, CXR wnl, mostly . This would be a very good group for a trial, could chose the patients carefully. For example, yest I saw an 89 yo in that group and the day before an 80 yo, also. Certainly these its may progress esp if recent COVID diagnosis.
B likely to do better stopping spread of virus- if we believe studies so far, or the conclusions as stated by authors and Leo. Unknown-totally-how big an impact the B anti inflammatory effect will be.
Part of the problem- giving a new drug to people not directly observed in a hospital to monitor for safety adverse events. So maybe those other ED trials would be done next. After initial in hospital trial. But will any other trials of B for C ever get a chance if initial trial is not successful? B may be a one and done if wrong trial population is selected
BvCED. B for C in ED. Take your pick. The B for C in the Emergency Dept Trial is one we need to start yesterday folks. So many sick people with so little therapy. In my state - Mass- alone over 2000 in hospital recently for COVID. With mostly supportive care.....
Please please please Leo get a move on and let's see if B for C helps patients-
One trial we need! In every ED there is a big group of people who do not require admission for COVID, and get no RX. They are sent home to see what the course of illness is. So give half B and half placebo and see how many return for admission, how many die, LOS etc etc.. The advantage of this group is that they receive no treatment- no Dex or Remdesivir , no nothing, usually. They go home to sit and wait it out and see what happens. Truly B vs no RX at all.
I would love to see that study. Lots of data available on such patients, easy to stratify, CBC Chem CRP Procalcitonin CXR 02 sats etc etc
Will we ever see this study?
Precisely. So little in the way of actual treatments and so many hospitalizations and deaths.Every shift I see another patient or 2 admitted with COVD.
Let's hope the trial starts soon. If only things had moved a bit faster over the summer- oh well.
I would hope that even if trial starts 2021 and not q4 that the group that promised not to post, still does post. IP and B need all the help they can get at this most crucial moment in company history.
I thought I would never get to write an order for Brilacidin. 2021 may change all that in a hurry. Imagine if B actually helps patients! The world will change drastically for the better and our shares will be worth a lot. Not a bad outcome-
In the meantime thoughts go out to all those suffering during the holidays- it is really tough in hospitals all across the country and around the world. Best wishes to all here, see you in 2021.
Got vaccine 0800 yest. My ED awash with COVID patients for a couple weeks now, many very ill. We start Dexamethasone and Remdesivir, and B? What an opportunity is now being missed by our company , if B is any good. So many hospitalized with corona virus with so little therapy-it is unbelievable, really. We wait for any word on a B trial and we get nothing at all as the quarter ends. Pundits here predicted actual data in mid Jan- OK then, bring it on Leo, get in the game.
So many potential patients for B, so many. So sad. Two days ago my first 4 patients had corona virus, and that is just one community ED near Boston. Heartbreaking to see so many suffer and die.
OK I said I was gone, and I am, mostly, but an update from the field a couple times a year may add something here. I do not think many of you are seeing patients day after day, doing badly, with so little to offer them. This is indeed ugly, even as the vaccinations start to offer some hope.
Best holiday wishes to IP and B- please get in the game
Best wishes to all here, and I mean that, believers and skeptics. Personally I find skepticism - constant rethinking- essential to doing a reasonable job in most walks of life. I apply the same standard to IP and its various moves over the years. I have been very wrong- I thought B for cellulitis was a very good bet, way back when. I still think it'd be a very useful drug for a lot of ED and hospital settings. But no B deal for cellulitis surfaced.
That is years ago already. With lots of water under the bridge.
It turns out not all value skepticism, and some are hostile even. My purpose here was to cast the same level of doubt that I cast on my everyday decisions in the ED. If that is offensive it was not intended. I subject myself and my decisions to much stricter scrutiny, I can assure you.
At any rate, it is time to move on. I express my hopes that all goes well with IP and Brilacidin esp, whether with viruses, or with ulcerative colitis, or whatever the future brings.
I am still hoping for the elusive B acne cream, in addition to a B inhaler , or B mask, to ward off viruses.
Best of luck to all here. I am not selling my shares either .
I remain a B-liever.
NEJM 9/17/2020 Slaoui et al beg to differ.
Still plenty of time to fasten seat belts-no ignition until positive human trial. Unless bought out by big Pharma sooner.
One other thing-for those who are upset about skeptics here- get a life. This is a very small stage.
they need larger hospitals not smaller
How about news? Since the preprint had none?
Yes folks, this is optimistic for me, I am trying. Let's go IP! Time to hear more of trials and funding, as some suggest. It is hard to imagine that some big Pharma is not ready to collaborate.
hey join the real world, where it has always been about skeptics vs believers. It is not about bashing or long v short. We are on the same side now hoping B can succeed v C. And who knows maybe even MERS or SARS. Firsts things first.
Or else we are all back to B UC.
Like you made your point. Not.
Wagers are dead
Violets are blue
Score counts are boring
That much is true
Look: long view of IP skeptics have carried the day- the share price is a good measure. Case closed.
But who cares? I do not care about being right about P2b or the fate of P or the stupid B OM subsets or the non-success of B OM. I am only interested, as you are, in seeing the company move forward.
I get it- it's now a new company and the past is gone, it's an antiviral company. Well, let's all hope so.
It will be a miracle if a trial succeeds and it remains a long shot despite what people say here.. Does not matter if it starts Dec 15 or not- q 4 who cares? Woulda been much better if it started Sept 15. They had the SI a long time ago.
We are now on the same side- skeptics and believers alike, as a trial approaches. Repeating myself: hope they pick the right trial or hope that somehow they can do several trials incl prophylaxis in some way shape or form.
And we can all hope together that B v C does succeed in some fashion.
yes a weird hodge podge, much more like an IP promotional than academic paper- though much in the supplements surely to be jettisoned- so why ever put there in the first place.
Thanks Leo for the update about trial funding, and the weird and wacky world of wagers, which need some clarification. What 3? Let's pretend that September and October witnessed a blastoff shall we? Maybe that was not your wager- how lucky.- but many made such a bet.
How likely is human trial success B for C? How likely data back by Jan 20?
Plenty of wagers out there, lots of room for failure. On both sides.
How about if we stick to the topic? You said I was dead wrong and I said you were totally correct about that. And then one wonders: if complete nonsense comes from the half full crowd do we just pretend it never happened? Or hold them to account?
Of course finishing VERO in April and then Lung cell mid June is slow. In the midst of a pandemic.
None of this has anything to do with medical school or EDs. Of course drug development is slow
But: look at the warp speed response to the pandemic with vaccine development. How about that? It is unprecedented and amazing. Then back to GMU and green monkey kidney data and then lung cell 2 months later- how warp is that?
Not warp for B. Could it be more obvious? Versus the vaccine example?
Parity perhaps, then? Sure we can go over this again. Why not? I thought the lung tests were too long in coming, and I was right about that. Slow slow slow during a pandemic.
Deadly slow.
I thought I meant the tests failed and I was wrong about that as I have said many times here already.
However: when others are way off base- blast off of the company in Sept no doubt, or high likelihood of B v C success for a human trial, is that "spamming the board with nonsense?" Or is it fine to be dead wrong if boosting the stock? That is fine, then?
How about a little parity?
Highly likely B v C success in human trial
If you plan it funding will come
Data out from human trial by middle Jan
Such is the wisdom of the glass half full . Such are the predictions
We shall see.
How big were Sept and Oct for IP shareholders? You know, the blastoff? The predicted ignition never occurred...so much for the half full predictions this fall to date.
Shares still available for twenty cents
Let's move the goalposts! sad really, jumping up and down to say that the paper proves Leo is not a liar. LOL. As if that were the point.
What a shift in attitude!
remember the predictions of lots of new data coming out with the preprint? So what happened? Nothing happened. All the new tests are in progress or planned.....
But let's move the goalposts -
Says who: multiple human trials most likely with funding?
Really? Wake up, wake up....
Then somebody really needs to pick up the pace
4/6 PR CEO says talking to FDA about human trials.
6/17 lung cell tissue data.
Where are we now with a trial? And funding? And multiple trials with funding?
It'd be nice but..lots of data floating around and lots of FDA chatter and no announcements yet obviously
Sober IP watchers- acclaimed -say data on B v C human trial ready by week 3 Jan.
Sober IP watchers say- if you plan it ,funding will come.
Sober IP watchers say high likelihood success of B v C in human trial.
Fine- we can all see how it plays out
VERO and lung cell and SI and Rem/B needed confirmation? You thought Leo made it all up? they repeat old news in a paper and it is suddenly a miracle? It is not.
Nothing new, sad to say.
How exciting.
much ado about old news. Good they finally got the paper out, but it had nothing Leo had not already released. Remember all the predictions of new tests that would be in the paper? So much for that. So much chatter in the paper about other tests that will be done. Just nothing new.
Why has there been no progress with FDA since all this stuff is old?
the glass was half full 4 months ago. Count 'em, 4.
That is a long time in the midst of a pandemic. A crack team at the RBL musta been all over this, right?
LOL
Why not? Why not expedited?
Also: how full is that grant glass? Not very.
umm, we had a lot of this news by June 17. We did not just get it
I know, I know, but what can I tell you. Isn't everyone a bit surprised how little was done, given all that time? Has anybody but Bakovic done any of the work,other than whatever the Rutgers person did? Talk about slow, slow slow. One grad student and what other army? Despite all the deaths and hospitalizations-
So much chatter about the FDA and the pandemic by CEO and this is where we are as the year ends.
Yes I am glad B has a shot v C. But we knew this 4 months ago....
I like the haiku lilt of the sentiment.
Do you think the pace of the testing and pre-pub is appropriate to the exigencies of the pandemic, as Leo wrote, way back in June the 6/17 PR?
I for one do not.
I am glad that IP and B are in the mix, but it's been a long time coming.
Grant??? everybody keeps talking about MERS and SARS and it ought to be promising but the grant that was submitted? Any update?
Not even a chance.
What is the truth? Why never an explanation?
Bakovic working on resubmission? Who knows- we certainly haven't a clue.
We're only shareholders after all.
PMX 30063 antiviral work? Some here have said there was a lot of antiviral stuff done by PMX with B, but they could not be bothered to look it all up and report back. I see that none of this was mentioned in the paper despite extensive lists of antibacterial and anti inflammatory info.
Maybe this never existed? And it was just made up? How about just making stuff up?
Prophylaxis again mentioned, no surprise. Will they even do the IV trial? With or without Remdesivir? It is going to take a lot longer to develop an inhaler or a nasal spray or a mask than q4. If an IV trial fails what will become of B? IP sells it at auction having run out of money?
Lots of questions.